PARP Inhibitor Safe Against BRCA-Associated Cancers

Elsevier Global Medical News. 2009 Jun 24, MA Moon

Olaparib had an acceptable side-effect profile and did not produce the usual toxic effects of chemotherapy in a small phase I study.

NOT A MEMBER?

OncologySTAT registration is FREE and takes less than a minute to complete. Registration provides instant access to 100+ Elsevier cancer-related journals, journal scans, daily medical and regulatory news, professional drug and interactions databases, chemotherapy regimens, and InfoBLAST - OncologySTAT's weekly e-newsletter.

 

Advisory and Editorial Boards

Meet OncologySTAT's Advisory and Editorial Boards that represent community practitioners and academic specialists with cross-disciplinary expertise.
Editorial Board › Advisory Board ›

Editors' Choice

Neoadjuvant Trastuzumab improves event-free survival in HER2+ locally advanced or inflammatory breast cancer.
Read more ›

Cancer Types Spotlight

more types
close
  • Bladder
  • Bone
  • Breast
  • CNS/Brain
  • Colon and Rectum
  • Endocrine System
  • Esophagus
  • GYN (Non-Ovary)
  • GYN (Ovary)
  • Head and Neck
  • HIV-Related Cancers
  • Hodgkin's Lymphoma
  • Bladder
  • Bone
  • Breast
  • CNS/Brain
  • Colon and Rectum
  • Endocrine System
  • Esophagus
  • GYN (Non-Ovary)
  • GYN (Ovary)
  • Head and Neck
  • HIV-Related Cancers
  • Hodgkin's Lymphoma
  • Kidney (Renal Cell)
  • Leukemia
  • Liver and Bile Duct
  • Lung
  • Multiple Myeloma
  • Myelodysplastic Syndrome
  • Myeloproliferative Diseases
  • Non-Hodgkin's Lymphoma
  • Pancreas
  • Pediatric Cancers
  • Prostate
  • Rare Cancers
  • Skin (Melanoma)
  • Skin (Non-Melanoma)
  • Soft-Tissue Sarcoma
  • Stomach
  • Testicle
    • Forgot your password?
    Not a member? Free registration